{"nctId":"NCT01307033","briefTitle":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","startDateStruct":{"date":"2011-03-29","type":"ACTUAL"},"conditions":["Hypertension"],"count":278,"armGroups":[{"label":"MK-954H (L50/H12.5)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: MK-954H","Drug: Placebo to MK-0954A"]},{"label":"MK-0954A (L100/H12.5)","type":"EXPERIMENTAL","interventionNames":["Drug: MK-0954A","Drug: Placebo to MK-954H"]}],"interventions":[{"name":"MK-0954A","otherNames":[]},{"name":"MK-954H","otherNames":["PreminentÂ®"]},{"name":"Placebo to MK-0954A","otherNames":[]},{"name":"Placebo to MK-954H","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Participant has a diagnosis of essential hypertension.\n* Participant is being treated with a single, or dual combination treatment for hypertension and will be able to discontinue the prior antihypertensive medication.\n* Participant has a mean trough SiDBP of \\>=90mmHg and \\< 110mmHg.\n* Participant has a mean trough SiSBP of \\>=140mmHg and \\< 200mmHg.\n* Participant has no clinically significant abnormality at screening visit.\n\nExclusion criteria:\n\n* Participant is currently taking \\> 2 antihypertensive medications.\n* Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-lotan or Preminent and thiazide drug or related drug (i.e., sulfonamide-containing \"chlortalidone\" medicines).\n* Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence.\n* Participant is pregnant or breastfeeding, or expecting to conceive or the pregnancy test is positive at screening visit.\n* Participant is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8","description":"Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"0.7"},{"groupId":"OG001","value":"-5.0","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8","description":"Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":null},{"groupId":"OG001","value":"-8.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0","spread":null},{"groupId":"OG001","value":"72.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":144},"commonTop":["Nasopharyngitis","Blood uric acid increased","Upper respiratory tract infection","Upper respiratory tract inflammation","Diabetes mellitus"]}}}